Gan & Lee Pharmaceuticals.

This study tests a new insulin called GZR4 that is given once a week, compared to a standard daily insulin, in adults with type 2 diabetes who have never used insulin before. About 580 participants will receive either the weekly shot or daily insulin, along with their usual diabe…

This phase 3 study tests a new injectable drug called GZR18 in about 1,100 Chinese adults with type 2 diabetes whose blood sugar is not well controlled by metformin or other oral medications. Participants receive either GZR18 or the approved drug semaglutide to compare how well e…

This study tests a new insulin (GZR4) given just once a week, compared to a standard daily insulin (glargine), in 580 adults with type 2 diabetes who already use mealtime insulin. The goal is to see if the weekly shot controls blood sugar as well or better, with fewer injections …

This Phase 3 study tests an injection called GZR18 for weight loss in 630 adults who are obese or overweight with related health issues. Participants receive either the drug or a placebo, and researchers measure weight change over time. The goal is to see if GZR18 is safe and eff…

This Phase 3 study tests an injectable drug called GZR18 in 274 Chinese adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. Participants receive either GZR18 or a placebo to see if the drug improves blood sugar levels, weight, and wais…

This phase 3 study tests a new insulin called GZR4 that is injected just once a week, compared to the standard daily insulin degludec. About 620 adults with type 2 diabetes who already use basal insulin will take part. The goal is to see if the weekly shot controls blood sugar ju…

This study tests two experimental injections, GZR102 (once a week) and GZR18 (every two weeks), in adults with type 2 diabetes whose blood sugar is not well controlled on current GLP-1 medications. About 90 Chinese participants will receive one of the two treatments to see which …

This study looks at how a single dose of the experimental drug GZR4 injection behaves in people with mild, moderate, or severe liver impairment compared to those with normal liver function. The goal is to understand the drug's safety and how the body processes it. 36 adults with …